Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atai Life Sciences (ATAI) stocks in Canada

Learn how to easily invest in Atai Life Sciences stocks.

Atai Life Sciences is a biotechnology business based in the US. Atai Life Sciences stocks (ATAI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.4 – a decrease of 11.41% over the previous week. Atai Life Sciences employs 35 staff and has a trailing 12-month revenue of around $20.1 million.

How to buy shares in Atai Life Sciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATAI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Atai Life Sciences stock price (NASDAQ:ATAI)

Use our graph to track the performance of ATAI stocks over time.

Atai Life Sciences shares at a glance

Information last updated 2022-01-25.
Latest market close$4.66
52-week range$4.66 - $22.91
50-day moving average $9.19
200-day moving average $13.72
Wall St. target price$28.46
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.94

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Atai Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Atai Life Sciences price performance over time

Historical closes compared with the close of $4.66 from 2022-01-27

1 week (2022-01-21) -11.41%
1 month (2021-12-28) -36.43%
3 months (2021-10-28) -67.14%
6 months (2021-07-28) -71.29%
1 year (2021-01-24) N/A
2 years (2020-01-24) N/A
3 years (2019-01-24) N/A
5 years (2017-01-24) N/A

Atai Life Sciences financials

Revenue TTM $20.1 million
Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $2.84
Market capitalisation $823.9 million

TTM: trailing 12 months

Atai Life Sciences share dividends

We're not expecting Atai Life Sciences to pay a dividend over the next 12 months.

Atai Life Sciences overview

Atai Life Sciences N. V. , through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site